BioMarin (BMRN) director Willard H. Dere receives 7,490-share RSU grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Dere Willard H reported acquisition or exercise transactions in this Form 4 filing.
BIOMARIN PHARMACEUTICAL INC director Willard H. Dere received a grant of 7,490 shares of common stock in the form of restricted stock units on June 2, 2026. The grant is recorded at a price of $0.00 per share, reflecting that it is a compensation award rather than a market purchase.
Following this award, Dere directly holds 46,440 shares of BioMarin common stock as reported in this filing. The footnotes clarify that the transaction represents restricted stock units, with price not applicable.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Dere Willard H
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 7,490 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 46,440 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
RSU grant size: 7,490 shares
Reported grant price: $0.00 per share
Shares held after grant: 46,440 shares
+1 more
4 metrics
RSU grant size
7,490 shares
Restricted stock units granted on June 2, 2026
Reported grant price
$0.00 per share
Compensation award, price not applicable per footnote
Shares held after grant
46,440 shares
Total direct BioMarin common stock holdings after transaction
Acquisition transactions
1 transaction
Form 4 shows one acquisition-type entry (code A)
Key Terms
Restricted stock units, Form 4, Grant, award, or other acquisition, Common Stock
4 terms
Restricted stock units financial
"Restricted stock units granted on June 2, 2026."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Form 4 regulatory
"According to a new Form 4."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Grant, award, or other acquisition financial
"transaction code description is Grant, award, or other acquisition."
Common Stock financial
"security title is Common Stock."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider transaction did BioMarin (BMRN) report for Willard H. Dere?
BioMarin reported that director Willard H. Dere received 7,490 shares as a restricted stock unit grant. This is a compensation-related equity award, not an open-market stock purchase or sale, and was dated June 2, 2026.
Was the BioMarin (BMRN) Form 4 transaction an open-market buy or sell?
The Form 4 shows a grant coded as an acquisition (A), representing 7,490 restricted stock units. The price is listed as $0.00 per share, indicating a compensation grant rather than an open-market purchase or sale.
What does the footnote on the BioMarin (BMRN) Form 4 transaction explain?
The footnote explains that the 7,490 units are restricted stock units granted on June 2, 2026, and that price is not applicable. This clarifies the award is a stock-based compensation grant with no cash price per share.
How is the Form 4 transaction for BioMarin (BMRN) classified by the SEC code?
The transaction uses code A, which stands for a grant, award, or other acquisition. This confirms the 7,490-share entry is a non-derivative equity award to Willard H. Dere rather than a market trade in BioMarin shares.